Cytosorbents CorporationCTSONASDAQ
Loading
Cash Generation ExpandingExpanding
Percentile Rank40
Studio
Year-over-Year Change

Operating cash flow minus capital expenditures

Latest
$-10.12M
↑ 34% vs avg
Percentile
P40
Within normal range
Streak
3 yr
Consecutive growthExpanding
Average
$-15.38M
Historical baseline
PeriodValueYoY Change
TTM$-10.12M+31.2%
2024$-14.71M+34.9%
2023$-22.59M+34.9%
2022$-34.69M-89.7%
2021$-18.29M-150.9%
2020$-7.29M+60.1%
2019$-18.28M-47.9%
2018$-12.36M-51.9%
2017$-8.14M-11.1%
2016$-7.33M-